Industry Overview

US brachytherapy market was valued at $764.1 million in 2025 and is projected to reach $1,590.1 million by 2035, growing at a CAGR of 7.7% during the forecast period (2026–2035). The market growth is driven by the increasing prevalence of cancer and the demand for minimally invasive treatments. High-Dose Rate (HDR) brachytherapy is the largest and fastest-growing segment. Its key growth drivers include technological advancements like improved imaging and AI, favorable reimbursement policies, and an aging population.

Market Dynamics

Rising Cancer Prevalence and Increasing Adoption of Minimally Invasive Oncology Treatments

The growing incidence of cancer, particularly prostate, breast, and gynecologic cancers, is a major factor driving the demand for brachytherapy in the US. According to the American Cancer Society, over 2 million new cancer cases are projected to be diagnosed in 2025, with prostate cancer remaining one of the most prevalent among men. Brachytherapy offers a highly localized and effective treatment option that minimizes damage to surrounding healthy tissues, making it particularly suitable for early-stage and localized cancers.

Moreover, the growing preference among patients and oncologists for minimally invasive and outpatient treatments is further propelling the adoption of brachytherapy over conventional external beam radiation therapy (EBRT). The ability to deliver higher radiation doses directly to tumors while reducing systemic side effects positions brachytherapy as a vital component of modern cancer treatment protocols across the US

Technological Advancements and Integration of Image-Guided Systems

Continuous technological progress in imaging, applicator design, and dose delivery precision has significantly enhanced the safety and effectiveness of brachytherapy procedures. The integration of advanced imaging modalities such as MRI, CT, and ultrasound into planning and real-time treatment guidance enables clinicians to achieve precise dose distributions and better tumor control. The rise of electronic brachytherapy systems, which eliminate the need for radioactive isotopes, has reduced logistical challenges and regulatory hurdles associated with radioactive source handling.

Furthermore, developments in automated afterloading systems and treatment planning software have streamlined clinical workflows, improving both accuracy and patient throughput. These innovations are encouraging a wider range of healthcare facilities, including community oncology centers and ambulatory surgery units, to offer brachytherapy services, thereby expanding market penetration across the US.

Favorable Reimbursement Landscape and Growing Outpatient Infrastructure

The favorable reimbursement environment for brachytherapy procedures in the US is another strong market driver. The Centers for Medicare & Medicaid Services (CMS) provides reimbursement for both low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy procedures, incentivizing hospitals and specialty clinics to adopt these technologies. Additionally, the shift toward outpatient cancer care—supported by cost-efficiency measures and improved safety outcomes has increased the utilization of brachytherapy in ambulatory and community-based oncology settings. With healthcare providers seeking methods that balance clinical efficacy and cost-effectiveness, brachytherapy aligns well with value-based care initiatives. This combination of supportive reimbursement policies, robust healthcare infrastructure, and growing awareness among clinicians and patients continues to strengthen the market’s growth trajectory across the US.

Market Segmentation

• Based on the indication, the market is segmented into breast cancer, gynecological cancer, prostate cancer, skin cancer, brain cancer, and others.
• Based on the type, the market is segmented into low-dose rate (LDR) brachytherapy and high-dose rate (HDR) brachytherapy.

Prostate Cancer to Lead the Market with the Largest Share

The single largest segment driving the US brachytherapy market is prostate cancer (by indication). Prostate brachytherapy (predominantly permanent low-dose-rate seed implants and complementary HDR boost strategies) consistently accounts for the largest share of revenue and procedures in US datasets.

Prostate applications benefit from long-established clinical protocols, strong evidence of durable oncologic outcomes for localized disease, comparatively lower total treatment cost versus extended external-beam regimens, and a well-developed supply chain for seeds and applicators; as a result, multiple market reports place the prostate segment as the market leader (commonly reporting roughly one-third to nearly half of total brachytherapy revenue depending on methodology). While HDR delivery is growing rapidly across indications because of workflow and safety advantages, the historical and continuing commercial weight of seed-based prostate programs keeps the prostate indication as the dominant single segment in the US brachytherapy market.

Market Players Outlook

The major companies operating in the US Brachytherapy market include Becton, Dickinson and Company (BD), Elekta AB, IsoRay Inc., Theragenics Corp., Varian Medical Systems, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In July 2025, iCAD, Inc. was acquired by RadNet, Inc.’s subsidiary DeepHealth. Although not exclusively a brachytherapy company, iCAD’s technology portfolio spans cancer-diagnosis and radiation therapy enabling tools; this acquisition influences downstream device and treatment technologies that integrate or complement brachytherapy workflows.

The Report Covers

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the US brachytherapy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.